Nothing Special   »   [go: up one dir, main page]

AR095338A1 - NON-TOXIC TREATMENT METHOD FOR DRUG ABSTINENCE - Google Patents

NON-TOXIC TREATMENT METHOD FOR DRUG ABSTINENCE

Info

Publication number
AR095338A1
AR095338A1 ARP140101042A ARP140101042A AR095338A1 AR 095338 A1 AR095338 A1 AR 095338A1 AR P140101042 A ARP140101042 A AR P140101042A AR P140101042 A ARP140101042 A AR P140101042A AR 095338 A1 AR095338 A1 AR 095338A1
Authority
AR
Argentina
Prior art keywords
treatment method
toxic treatment
drug abstinence
withdrawal
noribogaine
Prior art date
Application number
ARP140101042A
Other languages
Spanish (es)
Inventor
Friedhoff Lawrence
Original Assignee
Demerx Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Demerx Inc filed Critical Demerx Inc
Publication of AR095338A1 publication Critical patent/AR095338A1/en

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/55—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/47—Quinolines; Isoquinolines
    • A61K31/485—Morphinan derivatives, e.g. morphine, codeine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
    • A61P25/32—Alcohol-abuse
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
    • A61P25/36—Opioid-abuse
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/13—Amines
    • A61K31/135—Amines having aromatic rings, e.g. ketamine, nortriptyline
    • A61K31/137—Arylalkylamines, e.g. amphetamine, epinephrine, salbutamol, ephedrine or methadone

Landscapes

  • Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Addiction (AREA)
  • Epidemiology (AREA)
  • Neurology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Neurosurgery (AREA)
  • Biomedical Technology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Psychiatry (AREA)
  • Emergency Medicine (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)

Abstract

Reivindicación 1: Un método para el tratamiento de los síntomas de abstinencia en un paciente que padece de abstinencia de la adicción a una sustancia, que comprende la administración al paciente de una dosis de noribogaína que provee una Cₘₐˣ de noribogaína de menos de aproximadamente 1980 ng/mg de suero y una AUC/24 hs promedio de aproximadamente 1.100 ng/ml.Claim 1: A method for the treatment of withdrawal symptoms in a patient suffering from substance withdrawal withdrawal, which comprises administering to the patient a dose of noribogaine that provides a noribogaine Cₘₐˣ of less than about 1980 ng / mg of serum and an average AUC / 24 hours of approximately 1,100 ng / ml.

ARP140101042A 2013-03-15 2014-03-14 NON-TOXIC TREATMENT METHOD FOR DRUG ABSTINENCE AR095338A1 (en)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US201361852485P 2013-03-15 2013-03-15

Publications (1)

Publication Number Publication Date
AR095338A1 true AR095338A1 (en) 2015-10-07

Family

ID=51537436

Family Applications (1)

Application Number Title Priority Date Filing Date
ARP140101042A AR095338A1 (en) 2013-03-15 2014-03-14 NON-TOXIC TREATMENT METHOD FOR DRUG ABSTINENCE

Country Status (14)

Country Link
US (3) US20140288056A1 (en)
EP (1) EP2968355A4 (en)
JP (1) JP2016514679A (en)
KR (1) KR20150130461A (en)
CN (1) CN105307658A (en)
AR (1) AR095338A1 (en)
AU (1) AU2014228986A1 (en)
BR (1) BR112015022465A2 (en)
CA (2) CA2942638A1 (en)
EA (1) EA201591679A1 (en)
HK (1) HK1220381A1 (en)
TW (1) TW201505634A (en)
WO (2) WO2014143201A1 (en)
ZA (1) ZA201507514B (en)

Families Citing this family (16)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA2664335C (en) 2006-09-20 2014-12-02 Boehringer Ingelheim International Gmbh Rho kinase inhibitors
CA2942638A1 (en) 2013-03-15 2014-09-18 Demerx, Inc. Method for noribogaine treatment of addiction in patients on methadone
US9561232B2 (en) 2014-02-18 2017-02-07 Demerx, Inc. Low dose noribogaine for treating nicotine addiction and preventing relapse of nicotine use
WO2015126434A1 (en) 2014-02-18 2015-08-27 Demerx, Inc. Methods for acute and long-term treatment of drug addiction
CA2977636C (en) * 2014-02-18 2024-01-02 Demerx, Inc. Therapeutic methods employing noribogaine and related compounds
US9591978B2 (en) 2014-03-13 2017-03-14 Demerx, Inc. Methods and compositions for pre-screening patients for treatment with noribogaine
US9549935B2 (en) 2014-07-14 2017-01-24 Demerx, Inc. Methods and compositions for treating migraines using noribogaine
US9592239B2 (en) 2014-09-12 2017-03-14 Demerx, Inc. Methods and compositions for ibogaine treatment of impulse control disorder, anxiety-related disorders, violence and/or anger, or regulating food intake
EP3845275A1 (en) 2014-11-26 2021-07-07 DemeRx, Inc. Methods and compositions for potentiating the action of opioid analgesics using iboga alkaloids
WO2016134019A1 (en) * 2015-02-19 2016-08-25 Demerx, Inc. Methods for treating disorders associated with undesired activity of neuronal nicotinic acetylcholine receptors
CA3024081A1 (en) * 2015-05-11 2016-11-17 Demerx, Inc. Methods for treatment of opioid dependency and withdrawal using noribogaine
WO2017086941A1 (en) 2015-11-17 2017-05-26 Aerie Pharmaceuticals, Inc. Process for the preparation of kinase inhibitors and intermediates thereof
KR102409785B1 (en) 2017-03-23 2022-06-16 삼성전자주식회사 Apparatus and method for performing initial access in wireless communication system
GB2571696B (en) 2017-10-09 2020-05-27 Compass Pathways Ltd Large scale method for the preparation of Psilocybin and formulations of Psilocybin so produced
KR20220008824A (en) 2019-04-17 2022-01-21 컴퍼스 패쓰파인더 리미티드 How to treat anxiety disorders, headache disorders and eating disorders with psilocybin
US20220265675A1 (en) * 2019-07-15 2022-08-25 Demerx, Inc. Methods for the non-toxic treatment for opioid drug withdrawal combining noribogaine and cannabinoids

Family Cites Families (58)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US2817623A (en) 1956-03-22 1957-12-24 Ciba Pharm Prod Inc Tabernanthine, ibogaine containing analgesic compositions
US4626539A (en) 1984-08-10 1986-12-02 E. I. Dupont De Nemours And Company Trandermal delivery of opioids
US4806341A (en) 1985-02-25 1989-02-21 Rutgers, The State University Of New Jersey Transdermal absorption dosage unit for narcotic analgesics and antagonists and process for administration
US5149538A (en) 1991-06-14 1992-09-22 Warner-Lambert Company Misuse-resistive transdermal opioid dosage form
WO1996003127A1 (en) 1994-07-25 1996-02-08 Nda International, Inc. A method of treating chemical dependency in mammals and a composition therefor
US5591738A (en) 1994-10-14 1997-01-07 Nda International, Inc. Method of treating chemical dependency using β-carboline alkaloids, derivatives and salts thereof
US5616575A (en) 1995-12-04 1997-04-01 Regents Of The University Of Minnesota Bioactive tricyclic ibogaine analogs
ES2395268T3 (en) 1997-09-04 2013-02-11 Demerx, Inc. Noribogaine for the treatment of pain and drug addiction
US7220737B1 (en) 1997-09-04 2007-05-22 Novoneuron, Inc Noribogaine in the treatment of pain and drug addiction
US6416793B1 (en) 2000-07-11 2002-07-09 Bioresponse, L.L.C. Formulations and use of controlled-release indole alkaloids
US20030153552A1 (en) 2002-02-14 2003-08-14 Mash Deborah C. Method of treating chemical dependency in mammals and a composition therefor
US6939538B2 (en) * 2002-04-11 2005-09-06 Biomedical Research Models, Inc. Extended release analgesic for pain control
US6933308B2 (en) 2002-12-20 2005-08-23 Bristol-Myers Squibb Company Aminoalkyl thiazole derivatives as KCNQ modulators
US20060229293A1 (en) 2005-04-06 2006-10-12 Addiction Research Institute, Inc. Compositions for the treatment of hepatitis C and methods for using compositions for the treatment of hepatitis C
US8362007B1 (en) 2010-05-11 2013-01-29 Demerx, Inc. Substituted noribogaine
US8765737B1 (en) 2010-05-11 2014-07-01 Demerx, Inc. Methods and compositions for preparing and purifying noribogaine
US9394294B2 (en) 2010-05-11 2016-07-19 Demerx, Inc. Methods and compositions for preparing and purifying noribogaine
US8637648B1 (en) 2010-06-22 2014-01-28 Demerx, Inc. Compositions comprising noribogaine and an excipient to facilitate transport across the blood brain barrier
US9586954B2 (en) 2010-06-22 2017-03-07 Demerx, Inc. N-substituted noribogaine prodrugs
US8802832B2 (en) 2010-06-22 2014-08-12 Demerx, Inc. Compositions comprising noribogaine and an excipient to facilitate transport across the blood brain barrier
US8741891B1 (en) 2010-06-22 2014-06-03 Demerx, Inc. N-substituted noribogaine prodrugs
JP6049615B2 (en) 2010-07-23 2016-12-21 デマークス・インコーポレイテッドＤｅｍｅｒｘ，Ｉｎｃ． Noribogaine composition
WO2012024401A2 (en) 2010-08-17 2012-02-23 University Of Florida Research Foundation, Inc. Intelligent drug and/or fluid delivery system to optimizing medical treatment or therapy using pharmacodynamic and/or pharmacokinetic data
US8648198B2 (en) 2011-01-19 2014-02-11 Cold Spring Harbor Laboratory Phenylethanolamine-based NMDA receptor antagonists
EP2481740B1 (en) 2011-01-26 2015-11-04 DemeRx, Inc. Methods and compositions for preparing noribogaine from voacangine
CA2830511C (en) 2011-03-18 2021-09-14 Alkermes Pharma Ireland Limited Pharmaceutical compositions comprising aripiprazole lauroxil and sorbitan laurate
US8742096B2 (en) 2011-03-28 2014-06-03 Demerx, Inc. Methods and compositions for preparing noribogaine from voacangine
US10702485B2 (en) 2011-07-09 2020-07-07 Syntrix Biosystems Inc. Compositions and methods for overcoming resistance to tramadol
CN103857397B (en) 2011-09-15 2016-08-17 德莫科斯公司 Noribogaine salt non-solvent compound
CN104364256A (en) 2011-12-08 2015-02-18 德莫科斯公司 Stereoselective total synthesis of noribogaine
WO2013085922A1 (en) 2011-12-09 2013-06-13 Demerx, Inc. Phosphate esters of noribogaine
EP2788356A4 (en) 2011-12-09 2015-10-21 Demerx Inc Sulfate esters of noribogaine
CA2857969A1 (en) 2012-01-25 2013-08-01 Demerx, Inc. (1r,4r) 7-oxo-2-azabicyclo[2.2.2]oct-5-ene and derivatives thereof
AU2013212139A1 (en) 2012-01-25 2014-06-26 Demerx, Inc. Synthetic voacangine
US9150584B2 (en) 2012-01-25 2015-10-06 Demerx, Inc. Indole and benzofuran fused isoquinuclidene derivatives and processes for preparing them
EP2693223B8 (en) 2012-08-03 2021-09-08 ABB Schweiz AG Voltage measurement device with an insulating body
US8940728B2 (en) 2012-12-20 2015-01-27 Demerx, Inc. Substituted noribogaine
US9045481B2 (en) 2012-12-20 2015-06-02 Demerx, Inc. Substituted noribogaine
CA2942638A1 (en) 2013-03-15 2014-09-18 Demerx, Inc. Method for noribogaine treatment of addiction in patients on methadone
US9345711B2 (en) 2014-02-18 2016-05-24 Demerx, Inc. Methods for acute and long-term treatment of drug addiction
CA2977636C (en) 2014-02-18 2024-01-02 Demerx, Inc. Therapeutic methods employing noribogaine and related compounds
US9561232B2 (en) 2014-02-18 2017-02-07 Demerx, Inc. Low dose noribogaine for treating nicotine addiction and preventing relapse of nicotine use
WO2015126434A1 (en) 2014-02-18 2015-08-27 Demerx, Inc. Methods for acute and long-term treatment of drug addiction
US20150246055A1 (en) 2014-03-03 2015-09-03 Demerx, Inc. Methods for acute and long-term treatment of opioid and opioid-like drug addiction
US20150258114A1 (en) 2014-03-13 2015-09-17 Demerx, Inc. Methods for acute and long-term treatment of substance abuse using ibogaine
US20150258105A1 (en) 2014-03-13 2015-09-17 Demerx, Inc. Methods for acute and long-term treatment of alcohol dependence
US20150258107A1 (en) 2014-03-13 2015-09-17 Demerx, Inc. Methods and compositions for treating depression
US20150258106A1 (en) 2014-03-13 2015-09-17 Demerx, Inc. Methods for acute and long-term treatment of substance abuse
US9561233B2 (en) 2014-03-13 2017-02-07 Demerx, Inc. Use of ibogaine for the treatment of pain
US20150258111A1 (en) 2014-03-13 2015-09-17 Demerx, Inc. Methods and compositions for reducing tolerance to opioid analgesics using ibogaine and derivatives thereof
US9591978B2 (en) 2014-03-13 2017-03-14 Demerx, Inc. Methods and compositions for pre-screening patients for treatment with noribogaine
US20150258108A1 (en) 2014-03-13 2015-09-17 Demerx, Inc. Methods and compositions for reducing tolerance to opioid analgesics
EP3164402A1 (en) 2014-04-21 2017-05-10 DemeRx, Inc. N-substituted noribogaine prodrugs
US20150342959A1 (en) 2014-06-03 2015-12-03 Demerx, Inc. Methods and compositions for sustained noribogaine treatment
WO2015195673A2 (en) 2014-06-18 2015-12-23 Demerx, Inc. Halogenated indole and benzofuran derivatives of isoquinuclidene and processes for preparing them
US9549935B2 (en) 2014-07-14 2017-01-24 Demerx, Inc. Methods and compositions for treating migraines using noribogaine
EP3845275A1 (en) 2014-11-26 2021-07-07 DemeRx, Inc. Methods and compositions for potentiating the action of opioid analgesics using iboga alkaloids
WO2016134019A1 (en) 2015-02-19 2016-08-25 Demerx, Inc. Methods for treating disorders associated with undesired activity of neuronal nicotinic acetylcholine receptors

Also Published As

Publication number Publication date
CA2942638A1 (en) 2014-09-18
HK1220381A1 (en) 2017-05-05
EP2968355A2 (en) 2016-01-20
AU2014228986A1 (en) 2015-10-29
JP2016514679A (en) 2016-05-23
BR112015022465A2 (en) 2017-07-18
TW201505634A (en) 2015-02-16
ZA201507514B (en) 2018-05-30
US20160271139A1 (en) 2016-09-22
WO2014144508A2 (en) 2014-09-18
EA201591679A1 (en) 2016-05-31
US20150045350A1 (en) 2015-02-12
US9744174B2 (en) 2017-08-29
CN105307658A (en) 2016-02-03
US20140288056A1 (en) 2014-09-25
KR20150130461A (en) 2015-11-23
EP2968355A4 (en) 2016-08-24
CA2942511A1 (en) 2014-09-18
WO2014143201A1 (en) 2014-09-18

Similar Documents

Publication Publication Date Title
AR095338A1 (en) NON-TOXIC TREATMENT METHOD FOR DRUG ABSTINENCE
PH12015502691A1 (en) Use of high dose pridopidine for treating huntington's disease
MX2022003072A (en) Use of pridopidine for treating functional decline.
MX2021000898A (en) METHODS FOR TREATING PATIENTS WITH HETEROZYGOUS FAMILIAL HYPERCHOLESTEROLEMIA (heFH).
AR089862A1 (en) USE OF LAQUINIMOD FOR THE TREATMENT OF PATIENTS WITH CROHN'S DISEASE IN THOSE WHO FAILS AN ANTI-FACTOR THUMOR NECROSIS THERAPY a (ANTI-TNFa) FIRST LINE
AR097178A1 (en) DIAGNOSIS AND ANTI-CANCER THERAPIES THAT INCLUDE CANCEROSE MOTHER CELLS
AR090491A1 (en) TREATMENT OF MULTIPLE SCLEROSIS WITH A COMBINATION OF LAQUINIMOD AND DIMETILO FUMARATE
PE20142319A1 (en) MULTIPLE SCLEROSIS TREATMENT WITH A COMBINATION OF LAQUINIMOD AND GLATIRAMER ACETATE
AR091876A1 (en) PHARMACEUTICAL COMBINATIONS FOR THE TREATMENT OF PROLIFERATIVE DISEASES
PE20150161A1 (en) USE OF HIGH DOSE LAQUINIMOD FOR THE TREATMENT OF MULTIPLE SCLEROSIS
NZ715686A (en) Pharmaceutical for oral delivery comprising mgbg and methods of treating disease
AR097619A1 (en) USE OF ACETIL-COA CARBOXYLASE INHIBITORS TO TREAT ACNÉ VULGARIS
AR086422A1 (en) METHOD FOR THE TREATMENT OF ADVANCED SOLID TUMORS, VOLASERTIB
AR104771A1 (en) DRY POWDER INHALER
AR112482A1 (en) METHODS TO INCREASE AND / OR STABILIZE CARDIAC FUNCTION IN PATIENTS WITH FABRY'S DISEASE
MX2015009546A (en) Increased dosage of efavirenz for the treatment of cancer.
UY35890A (en) USE OF LAQUINIMOD TO DELAY THE PROGRESSION OF HUNTINGTON'S DISEASE
CL2012002942A1 (en) Use of a synthetic derivative of retinol and butylated hydroxyanisole dissolved in soybean oil to prepare a useful medicine in the treatment of a human subject suffering from the loss or deterioration of the vision caused by an 11-cis retinol deficiency disorder produced endogenously; pharmaceutical composition.
AR065139A1 (en) MEDICATION FOR THE TREATMENT OF ENDOMETRIOSIS
AR099299A1 (en) INHIBITOR OF THE CHOLESTERILE ESTER TRANSFER PROTEIN (CETP) AND PHARMACEUTICAL COMPOSITIONS THAT INCLUDE SUCH INHIBITOR FOR USE IN THE TREATMENT OR PREVENTION OF CARDIOVASCULAR DISEASES
UA109544C2 (en) PHARMACEUTICAL COMPOSITION CONTAINING PARACETAMOL AND METHOD OF MANUFACTURING
BR112015012497A2 (en) pharmaceutical combinations
BR112017017608A2 (en) methods for treating schizophrenia or a symptom of schizophrenia, to prevent a schizophrenic relapse and to maintain the effect of iloperidone for schizophrenia.
CL2011002863A1 (en) Use of a composition comprising nandrolone and a vitamin D compound to prepare a parenteral medicament useful for the treatment or prevention of frailty in an elderly patient; and a composition comprising nandrolone and a vitamin D compound, in a liquid carrier suitable for parenteral administration.
UY35748A (en) LAQUINIMOD COMBINED THERAPY FOR THE TREATMENT OF MULTIPLE SCLEROSIS

Legal Events

Date Code Title Description
FB Suspension of granting procedure